Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397814 | 0.84 | KDM4E (0.43) | TAAR1ALDH1A1KMT2AHPGDPTGS1 | |
| SCHEMBL2250015 | 0.81 | TRPA1 (0.47) | ALDH1A1TSHRPTGS1PTGS2MAPT | |
| SCHEMBL1932532 | 0.79 | ALDH1A1 (0.55) | TAAR1ALDH1A1KMT2APTGS1PTGS2 | |
| SCHEMBL1932534 | 0.79 | ALDH1A1 (0.55) | TAAR1ALDH1A1KMT2APTGS1PTGS2 | |
| SCHEMBL8368839 | 0.78 | TSHR (0.46) | TAAR1ALDH1A1KMT2AGAAHPGD | |
| SCHEMBL19357314 | 0.77 | CHRM5 (0.47) | ALDH1A1KMT2AACHECCNB2CDK1 | |
| SCHEMBL3066574 | 0.76 | NQO2 (0.42) | ALDH1A1KMT2AGAAHPGDPTGS1 | |
| SCHEMBL1988589 | 0.75 | TAAR1 (0.48) | TAAR1ALDH1A1KMT2AGAAHPGD | |
| SCHEMBL8397406 | 0.74 | TAAR1 (0.45) | TAAR1ALDH1A1KMT2ACYP2A6CYP2A13 | |
| SCHEMBL6085811 | 0.73 | TAAR1 (0.46) | TAAR1ALDH1A1KMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119667-B2 | Carbonates of fenicol antibiotics | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2012-02-21 | — | — | US | claimed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| CN-109232576-B | 7-substituted desoxypeganone base and preparation method and application thereof | 信阳师范学院 | 2020-07-17 | — | — | CN | disclosed |
| WO-2013187978-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| US-7538215-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-11-24 | — | — | US | disclosed |
| US-6903088-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | TAAR1 3380/4885ALDH1A1 322/4885KMT2A 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.